drugset
drugset / Trial / NCT00097227

Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00097227 ↗

Phase 2 Completed 165 enrolled Eli Lilly and Company Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.

Timeline

Start
2004-11
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 6 unknown Intravenous
Comparator Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 100 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 225 mg/m2 Intravenous

Indications

non-small cell lung carcinoma